Redefining Translational Science, Jarrod Tremayne, PhD , Is Appointed Vice President Of Translational Research And Early Development At Mercaptor

Published: Oct 02, 2017

NOVATO, Calif., Sept. 29, 2017 /PRNewswire/ -- Mercaptor Discoveries, a preclinical-stage pharmaceutical company developing therapies based on proprietary injury-activated, brain-protecting technology, announced today the promotion of Jarrod Tremayne, PhD, to the position of Vice President of Translational Research and Early Development.

Dr. Jarrod Tremayne. V.P. of Translational Research and Early Development

Dr. Tremayne combines an instinctive feel for discovery research, where he began his career, and fluency in the later-stages of drug-development, including human studies. Each of these talents is brought to bear in his translation efforts:  Starting with the transition from bench to disease models, reorienting higher up the pipeline to cover efficacy and toxicity, pushing forward to an IND, and finally, designing and managing Phase I studies.

An established member of the Mercaptor executive team, Dr. Tremayne began by using basic science data to design comprehensive preclinical model studies.  Placed in a position historically burdened by resistance from clients on both ends of the pipeline, Tremayne has invented ways to efficiently shepherd Mercaptor's work toward the clinic.  Embracing a company that, like its science, lacks precedent, Tremayne often strives to introduce lateral thinking into problem-solving, and is suspicious of perceived wisdom.  He keeps an unwavering eye on the prize: capturing and managing the data that will drive Mercaptor's lead advancement.  Jarrod helps the Mercaptor crew to understand how each part of his job increases the chances of overcoming the many looming hurdles.

"Jarrod is family.  Everyone feels the greatest respect for his efforts on Mercaptor's behalf," said Sara Isbell, President and CEO. "Our respect is only matched by our affection. We know how fortunate we are to have found someone so knowledgeable on the topic of orthodox drug-development, and, at the same time, so youthfully captivated by scientific treasure hunts."

Dr. Tremayne received his PhD in Pathology and Microbiology from the University of Nebraska Medical Center, as well as a B.S. in Animal Sciences from the University of Nebraska-Lincoln.

"I am inspired by my colleagues at Mercaptor Discoveries. By taking responsibility for developing astonishing discoveries into medical practice, Mercaptor is traveling quickly toward potential treatments for TBI, CTE, and a host of chronic neurodegenerative diseases," Dr. Tremayne stated. "I get to swim every day in the pool of scientific inquiry with some of my good friends.  I feel very lucky."

About Mercaptor Discoveries
Mercaptor Discoveries is a privately held company that was founded in October 2016 by a team of scientists who discovered an injury-activated molecule with potential to mitigate brain damage when used prophylactically and treat many neurodegenerative diseases. They took a leap of faith and became a self-seeded enterprise with a clear goal: adapting their discovery to treat seizures, TBI, Alzheimer's disease, ALS, chronic traumatic encephalopathy, Parkinson's disease, stroke, and other debilitating conditions. Headquartered in Novato, California, Mercaptor prioritizes science, promotes productivity and transparency, and values the purity of research.

Media Contact:
Carole Barrow


 (PRNewsfoto/Mercaptor Discoveries Inc.)

View original content with multimedia:

SOURCE Mercaptor Discoveries

Back to news